Compare Entegris Inc (ENTG) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Natera Inc. Common Stock — how do they compare? Entegris Inc trades at $145.48 (market cap $24.63B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.3× Entegris Inc's market cap, and Entegris Inc pays a 0.25% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Natera Inc. Common Stock for 0 Days on average.
| ENTG | NTRA | |
|---|---|---|
Market Cap | $24.63B | $57.03B |
Volume | 2,062,440 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $184.00 | $425.64 |
52-Week Low | $68.80 | $179.42 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $27.83B | $56.18B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Entegris (ENTG) trades at $153.08, down 4.33% amid broader market weakness, yet maintains strong analyst support with a $186.56 consensus price target. The semiconductor materials company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.93 surpassing expectations by 13%. Technical indicators show a bullish moving average trend while fundamentals reveal elevated valuation metrics (P/E 80.58) offset by robust profitability (9.18% net margin) and positive cash flow generation.
Investment outlook remains favorable given Entegris's positioning in high-growth semiconductor segments and AI-driven demand, though valuation concerns and debt levels warrant monitoring. The stock offers 22% upside to consensus targets but faces execution risks in a cyclical industry. Recent institutional accumulation and patent defense successes provide additional confidence in the company's competitive moat.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
